VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Angiogenesis inhibitor molecules defend against the development and spread of cancer

Research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) helps explain how a group of angiogenesis inhibitor molecules serve as an important defense mechanism against the development and spread of cancer, offering key insights into why cancerous tumors grow at different rates among different individuals.

15 Feb 2005

Gene therapy for heart patients with chest pains who do not benefit from other treatments

Individuals with moderate to severe chest pains (angina) who have not found relief from medication may benefit from a new gene therapy approach being used by cardiologists at Rush University Medical Center to grow new blood vessels in the heart.

3 Feb 2005

Research leads to new antiangiogenic drugs

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies.

17 Jan 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Novel approach to bioengineer artificial skin for burn victims

Each year more than 45,000 Americans suffer burns serious enough to require a hospital stay, according to the American Burn Association. While the traditional therapy of using skin grafts to cover burn sites has improved, a number of problems including scarring, infection and poor adhesion remain.

4 Jan 2005

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD), according to a paper in the Dec. 30 issue of the New England Journal of Medicine. Macugen was approved by the Food and Drug Administration on Dec. 17.

30 Dec 2004

Timing of radiation and antiangiogenic therapy impacts treatment effectiveness

Agents designed to attack blood vessels that feed a growing tumor are effective against tumor growth in laboratory experiments. However, results of early clinical trials with these inhibitors have not yet exhibited the same success observed in animal models.

20 Dec 2004

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

20 Dec 2004

Model may explain how alcohol stimulates tumor growth

The investigators found that compared to the saline control group, the embryos exposed to ethanol experienced increases in tumor size, tumor blood vessel density, cancer cell infiltration of blood vessels, and VEGF levels.

13 Dec 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

New possibilities for the use of VEGF in the treatment of Amyotrophic Lateral Sclerosis

ALS is an incurable, paralyzing neurodegenerative disorder that strikes 5 persons in every 100,000. The disease commonly affects healthy people in the most active period of their lives − without warning or previous family history.

29 Nov 2004

Overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) reduces tumor growth

Scientists have found that overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) blocks the formation of new blood vessels and thus reduces tumor growth. Therapeutics based on this finding may potentially lead to new cancer treatments.

19 Nov 2004

Scientists have found that a protein present in normal body tissues can prevent tumour growth

A team led by Dr Dave Bates, British Heart Foundation Lecturer, and Dr Steve Harper, Senior Research Fellow in the Microvascular Research Laboratories, in the Department of Physiology at Bristol University, have discovered that a type of vascular endothelial growth factor (VEGF) found in normal tissue, including blood, can prevent cancers from growing.

1 Nov 2004

Potential new treatment strategy against metastatic cancer cells

A team of scientists at The Scripps Research Institute has identified a potential treatment strategy against metastatic cancer cells that has never been tried before.

25 Oct 2004

Researchers stimulate the body to repair tissue damaged by peripheral arterial obstructive disease

Duke University Medical Center researchers have shown that they can stimulate the body to produce its own naturally occurring growth factors to promote blood vessel growth into tissue damaged by peripheral arterial obstructive disease (PAOD).

13 Oct 2004

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

HER-2 cell surface receptors tun on genes associated with carcinogenesis

Researchers at The University of Texas M. D. Anderson Cancer Center now have evidence that receptors found on tumors that were believed to function only on the surface of cells can actually switch on genes inside a cell's nucleus, thus promoting cancer development in two distinct ways.

21 Sep 2004

Drug combo may have a greater impact on cancer development

Cancer researchers have long suggested that new targeted drugs may work best when paired with other therapies. In a new study published today in Cancer Research, scientists have taken some of the first steps to demonstrate this synergy in mouse and cell line models.

16 Sep 2004

Novel pharmacological target for cannabinoid-based therapies

Cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to brain tumors by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).

15 Aug 2004